X-Chem, Inc. today announced the appointment of Christelle Huguet, Ph.D. as Chief Scientific Officer, along with an executive leadership appointment for Matthew Clark, Ph.D. as Senior Vice President, Chemistry.
Archive | news
X-Chem Announces Licensing of Two Discovery Programs to AbbVie
Small molecule drug discovery specialist XChem, Inc. today announced that AbbVie has exercised options to license two discovery programs. Under the terms of the parties’ 2016 multi-target research collaboration, AbbVie had an option to an exclusive license to the programs, each of which comprises multiple novel, cell-active modulators of two historically challenging targets in oncology […]
X-Chem Enters Expanded Global Drug Discovery and Technology Transfer Collaboration with AstraZeneca
WALTHAM, Mass. – January 17, 2018 – Small molecule discovery specialist X-Chem, Inc. today announced a significant expansion of their existing global drug discovery collaboration with the global biopharmaceutical company AstraZeneca.
X-Chem Provides Year-End Update on Partnership Achievements
X-Chem, Inc. announces that it has licensed its 40th drug discovery program to an undisclosed large Pharma partner, granting exclusive rights to novel small molecules that interact with the partner’s therapeutic target of interest.
Otsuka and X-Chem Enter into a Drug Discovery Research and License Collaboration
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and X-Chem, Inc. (X-Chem) announce that they have signed a collaborative research agreement to advance the discovery process for new Otsuka drug compounds.
X-Chem and Abilita Bio Announce a Joint Research Collaboration
(XChem), and Abilita Bio, Inc. (Abilita), both privately held biotechnology companies, announce today a joint research collaboration that will leverage the synergy between each company’s platform technology to enable the discovery of novel modulators of high-value G-protein coupled receptors (GPCR) and ion channel targets.
X-Chem and Gilead Announce Drug Discovery Collaboration
WALTHAM, Mass. – November 28, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Gilead Sciences, Inc. (Gilead). Under the terms of the agreement, XChem will screen its proprietary DEXTM libraries, which contain […]
Consortium of X-Chem, Harvard T.H. Chan School of Public Health and Other Leading Academic Institutions Wins Research Award from the Department of Defense
X-Chem, Inc., a privately held biotechnology company with a proprietary and innovative platform to generate small molecule therapeutics, today announced the award of a DOD CDMRP research grant entitled “Chemigenomic Drug Discovery for Tuberculosis.” The grant was awarded to a research consortium led by Eric Rubin, M.D., Ph.D., Irene Heinz professor of Immunology and Infectious […]
X-Chem further expands Collaboration with Bayer to Discover Novel Medicines
WALTHAM, Mass. – October 3rd, 2017 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics based on an industry leading DNA-encoded library containing over 120 billion small molecules, and Bayer have further expanded their drug discovery collaboration across multiple therapeutic […]
X-Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration
[Download PDF] X-Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration – Agreement will enable discovery of small-molecule leads against validated targets for severe, genetic diseases – X-Chem to receive upfront payment and potential research, development and regulatory milestones and licensing fees, plus additional royalties on future sales WALTHAM, Mass. – May 15, 2017 – […]